Therapeutic impact of mesenchymal stem cells on idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation

被引：0

作者：

Kamoi, Chihiro ^{[1
,2
]}

Terao, Toshiki ^{[3
]}

Kambara, Yui ^{[3
]}

Seike, Keisuke ^{[1
]}

Fujiwara, Hideaki ^{[1
]}

Asada, Noboru ^{[1
]}

Ennishi, Daisuke ^{[1
,4
]}

Nishimori, Hisakazu ^{[1
,5
]}

Fujii, Keiko ^{[1
,6
]}

Fujii, Nobuharu ^{[1
,2
]}

Maeda, Yoshinobu ^{[1
]}

Matsuoka, Ken-ichi ^{[1
,7
]}

机构：

[1] Okayama Univ, Okayama Univ Hosp, Grad Sch Med, Dept Hematol Oncol & Resp Med, 2-5-1 Shikata Cho,Kita Ku, Okayama 7008558, Japan

[2] Okayama Univ Hosp, Div Transfus & Cell Therapy, Okayama, Japan

[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med, Okayama, Japan

[4] Okayama Univ Hosp, Ctr Comprehens Genom Med, Okayama, Japan

[5] Hiroshima City Hiroshima Citizens Hosp, Dept Hematol, Hiroshima, Japan

[6] Okayama Univ Hosp, Div Clin Lab, Okayama, Japan

[7] Tokushima Univ, Grad Sch Biomed Sci, Dept Hematol Endocrinol & Metab, Tokushima, Japan

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2025年

关键词：

Mesenchymal stem cells; Graft-versus-host disease; Allogeneic hematopoietic stem cell transplantation; Idiopathic pneumonia syndrome; VERSUS-HOST-DISEASE; BRONCHIOLITIS OBLITERANS SYNDROME; STROMAL CELLS; THROMBOTIC MICROANGIOPATHY; PULMONARY COMPLICATIONS; ADULT PATIENTS; BLOOD; LUNG; COTRANSPLANTATION; ETANERCEPT;

D O I：

10.1007/s12185-025-04013-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Mesenchymal stem cells (MSCs) effectively treat steroid-refractory acute graft-versus-host disease (aGVHD). However, their impact on patients with both steroid-refractory aGVHD (SR-aGVHD) and idiopathic pneumonia syndrome (IPS) is unclear. This retrospective study analyzed 24 patients who received MSCs as a secondary treatment for SR-aGVHD, including 6 who also had IPS. The 180-day overall survival rate was 52.0%, with a relapse rate of 13.3% and non-relapse mortality at 34.7%. The clinical course was compared between the six patients with concurrent IPS and SR-aGVHD who received MSCs and the 36 IPS patients who did not receive MSCs. The 6 MSC-treated patients had a higher 2-year overall survival rate than the control group, at 83.3% versus 61.1%, with all patients showing reduced oxygen requirements and improved imaging findings. Among the five patients who survived longer than 2 months after MSC therapy, the median time to complete oxygen therapy was 28 days, and steroid doses were reduced by 25% at the 2-month mark. Some patients showed improved pulmonary function after MSC therapy. These findings support MSCs as a promising treatment for SR-aGVHD and suggest potential benefits in IPS.

引用

页数：16

共 54 条

[11] Targeting the Canonical Nuclear Factor-κB Pathway with a High-Potency IKK2 Inhibitor Improves Outcomes in a Mouse Model of Idiopathic Pneumonia Syndrome [J].